Soley Therapeutics combines AI with molecular and cellular response detection for developing new efficacious drugs.
Soley Therapeutics combines AI with molecular and cellular response detection for developing new efficacious drugs.
Drug Discovery📍 South San Francisco, CAFounded 2020
Current Valuation
$700M
as of 2024-Q3
PRIVATE
QL Price
$655.17M
-6% vs last round
QuantLogix's current estimate for Soley Therapeutics, published 2026-09-27 — below the last disclosed round of $700M (2024-Q3).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$700M
2024-Q3
weight 0.25
Secondary market print
$635.6M
2026-06-27
weight 0.58
How this price has held up
No round has priced for Soley Therapeutics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Soley Therapeutics, 2026-09-27 (96383766424e2633).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Soley Therapeutics going public?
No. Soley Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Soley Therapeutics' valuation in 2026?
Soley Therapeutics is valued at $700M as of 2024-Q3, set by its Series C ($200M, Sep 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Soley Therapeutics filed an S-1?
No public S-1 is on file for Soley Therapeutics.
How much has Soley Therapeutics raised?
Soley Therapeutics has raised $290.03M in total, most recently a Series C of $200M in Sep 2024.
Is Soley Therapeutics publicly traded — can you buy Soley Therapeutics stock?
No. Soley Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Soley Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2020
HQ
South San Francisco, CA
Employees
39
Total Raised
$290.03M
Last Round
Series C — $200M (Sep 2024)
IPO Status
private
Fundraising Status
Series C · $200M · 2y ago
privateTotal raised $290.03M
Secondary Market
Implied price / share
$21
Last round price / share
$23.14
vs last round
-9.2%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$200M
Sep 2024
—
$700M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Soley Therapeutics — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
3
via careers page
Product-build share
67%
engineering, research, product, design
Trajectory
steady
heavy product build — 67% of open roles are product-building functions (engineering/research/product) — 1 of 3 open roles are marketing.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Biotech Web DesignLet biology leadSkip to content
Counted from Soley Therapeutics's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareBiotechnologyTherapeutics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q3. Refreshed quarterly.